Report : Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)   

At 7.2% CAGR, the Europe Influenza Vaccines Market is speculated to be worth US$ 3,424.02 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe influenza vaccines market was valued at US$ 2,261.85 million in 2022 and is expected to reach US$ 3,424.02 million by 2028, registering an annual growth rate of 7.2% from 2022 to 2028. The strong pipeline candidates for influenza vaccines and increase in government support to promote influenza vaccination are the critical factors attributed to the market expansion.

Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats.

On the contrary, high cost of vaccine development hurdles the growth of Europe influenza vaccines market.

Based on vaccine type, the Europe influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment held 88.4% market share in 2022, amassing US$ 1,998.51 million. It is projected to garner US$ 3,073.81 million by 2028 to expand at 7.4% CAGR during 2022–2028.

Based on virus type, the Europe influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held 95.7% market share in 2022, amassing US$ 2,164.77 million. It is projected to garner US$ 3,309.85 million by 2028 to expand at 7.3% CAGR during 2022–2028.

Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held 79.1% market share in 2022, amassing US$  1,789.87  million. It is projected to garner US$ 2,668.13 million by 2028 to expand at 6.9% CAGR during 2022–2028.

Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held 72.7% market share in 2022, amassing US$  1,644.73 million. It is projected to garner US$  2,539.21 million by 2028 to expand at 7.5% CAGR during 2022–2028.

Based on country, the Europe influenza vaccines market is categorized into the UK, Germany, France, Italy, Spain, and the rest of Europe. Our regional analysis states that the UK captured 26.6% market share in 2022. It was assessed at US$ 602.15 million in 2022 and is likely to hit US$ 960.44 million by 2028, exhibiting a CAGR of 8.1% during the forecast period.

Key players dominating the Europe influenza vaccines market are AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd among others.

Contact Us

Contact Person: Sameer Joshi

Phone: +1- 646- 491- 9876

Email id: sam@businessmarketinsights.com

Download Free PDF Brochure